Imjudo

Tremelimumab, the active ingredient in Imjudo, is an immune checkpoint inhibitor presented as a solution for infusion for intravenous use. It is employed in the treatment of advanced cancers, most notably unresectable or metastatic melanoma, where it is given in combination with other immunotherapies to enhance the anti‑tumor immune response.

GNH USA supplies Imjudo as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide. The company adheres to stringent quality standards and provides cold‑chain logistics for biologic products through regulated distribution channels.

Imjudo (tremelimumab) targets the CTLA‑4 immune checkpoint and is used in oncology for specific advanced solid tumours. - Unresectable or metastatic melanoma: combined with durvalumab to extend overall survival in patients with non‑resectable disease. - Advanced melanoma after prior checkpoint therapy: provides an additional immunologic option to reactivate T‑cells. - High‑risk melanoma post‑surgery (adjuvant): studied to lower recurrence risk by sustaining immune surveillance. - Melanoma with high tumor mutational burden: may respond better to CTLA‑4 blockade due to increased neoantigen load.

Tremelimumab may cause a range of immune‑related adverse reactions, varying from mild to severe.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Rash: skin redness or itching. - Diarrhea: loose stools of mild to moderate severity. - Infusion‑related reactions: fever, chills, or flushing during administration.

Serious or Rare Side Effects: - Colitis: severe colon inflammation that can cause abdominal pain and bloody stools. - Hepatitis: liver inflammation with elevated enzymes and possible jaundice. - Endocrinopathies (e.g., hypophysitis, thyroiditis): hormonal disturbances requiring medical management. - Myocarditis: inflammation of the heart muscle that may lead to chest pain or arrhythmia.

When using Imjudo, careful monitoring and specific precautions are essential to minimise immune‑related toxicity. - Baseline assessment: evaluate organ function (liver, kidney, endocrine) before initiating therapy. - Immune monitoring: regularly check for signs of colitis, hepatitis, pneumonitis, and endocrine disorders during treatment. - Concomitant immunosuppression: avoid or limit use of other immunosuppressive agents that may reduce efficacy. - Live vaccines: do not administer live or attenuated vaccines while receiving tremelimumab. - Pregnancy and lactation: defer treatment in pregnant or breastfeeding individuals unless benefits outweigh risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the infusion solution.

Tremelimumab can interact with other medicines, influencing safety or therapeutic effect.

Major Interactions (Avoid): - Concurrent use with other immune checkpoint inhibitors: markedly increases risk of severe immune‑related adverse events. - Live or attenuated vaccines: may cause uncontrolled infection due to immune modulation. - High‑dose corticosteroids: can diminish the antitumor activity of tremelimumab. - Organ transplant recipients: heightened risk of graft rejection; generally contraindicated.

Moderate Interactions (Monitor Closely): - Systemic immunosuppressants (e.g., azathioprine): may reduce efficacy and require dose adjustment. - Anticoagulants: increased risk of bleeding if immune‑mediated thrombocytopenia occurs. - Hormone replacement therapy: may mask endocrine side effects, necessitating closer monitoring. - Antibiotics affecting gut flora: may alter immune response, monitor for infection.